Janssen Pharmaceuticals is seeking to move the growing litigation over its diabetes medication Invokana from state to federal court.
Drugmaker Janssen Pharmaceuticals recently filed notices in more than 100 cases pending in the Philadelphia Court of Common Pleas indicating it removed the cases to federal court. Although the copies of the notices of removal were filed in state court on Nov. 17, the notices were initially filed in the U.S. District Court for the Eastern District of Pennsylvania in early November.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
